Lantheus (LNTH) Stock Rating Lowered by BidaskClub

Lantheus (NASDAQ:LNTH) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Other equities research analysts have also recently issued research reports about the company. Jefferies Group increased their price target on Lantheus from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Zacks Investment Research raised Lantheus from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research note on Friday, January 12th. Finally, ValuEngine raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, February 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $24.75.

Shares of Lantheus (NASDAQ LNTH) traded up $0.25 during mid-day trading on Thursday, hitting $19.95. The stock had a trading volume of 300,702 shares, compared to its average volume of 268,353. The firm has a market capitalization of $748.24, a PE ratio of 24.63, a price-to-earnings-growth ratio of 1.29 and a beta of 0.95. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41. Lantheus has a 12 month low of $9.00 and a 12 month high of $24.45.

In related news, CFO John W. Crowley sold 3,866 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $23.52, for a total transaction of $90,928.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Timothy G. Healey sold 11,314 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $21.51, for a total value of $243,364.14. The disclosure for this sale can be found here. Insiders have sold 48,752 shares of company stock valued at $1,077,129 in the last ninety days. 2.30% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Lantheus by 1.7% during the fourth quarter. BlackRock Inc. now owns 3,808,620 shares of the medical equipment provider’s stock worth $77,887,000 after purchasing an additional 63,687 shares during the period. Vanguard Group Inc. grew its stake in Lantheus by 87.5% during the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after purchasing an additional 689,954 shares during the period. LSV Asset Management boosted its holdings in Lantheus by 57.5% in the fourth quarter. LSV Asset Management now owns 953,906 shares of the medical equipment provider’s stock worth $19,507,000 after acquiring an additional 348,298 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Lantheus by 73.7% in the third quarter. Dimensional Fund Advisors LP now owns 911,311 shares of the medical equipment provider’s stock worth $16,221,000 after acquiring an additional 386,771 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Lantheus by 12.6% in the second quarter. Renaissance Technologies LLC now owns 691,000 shares of the medical equipment provider’s stock worth $12,196,000 after acquiring an additional 77,200 shares in the last quarter. 91.07% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Lantheus (LNTH) Stock Rating Lowered by BidaskClub” was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/11/lantheus-lnth-stock-rating-lowered-by-bidaskclub.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply